Further investigation of how ISO targets key molecules and pathways such as HIF1a signaling and the PI3K/AKT/mTOR pathway to facilitate its cancer inhibitory effects, is necessary for maximizing its effectiveness as a cancer therapeutic drug. This evidence concerns the gene MTOR and cancer.